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INTRODUCTION 
In an effort to insure the birth of healthy infants, obstetricians 
have been searching for parameters by which they can safely evaluate 
fetal development. Amniocentesis has provided a valuable tool for 
studying fetal metabolic products. Of special value in amniocentesis 
is any element that can be proven to be of fetal origin and can therefore 
solely reflect fetal growth and development. 
A protein specific for the fetus was first described in fetal calf 
24 
serum by Pedersen in 1944. A similar protein was originally demon¬ 
strated in the human fetus by Bergstrand and Czar-’ in 1956. This pro¬ 
tein, of molecular weight 70, 000, occupied the region of the alpha- 
globulins during electrophoresis, and was named alpha-fetoprotein (AFP). 
Gitlin and Boesman, in 1967, determined the sites of alpha- 
fetoprotein synthesis in human and rat embryos. They incubated the 
14 
following tissues with C labeled amino acids: brain, heart, intestines, 
kidney, liver, lung, skeletal muscle, placenta, and skin from the human 
and rat, and the yolk sac from the rat. Using rabbit antisera to AFP, 
and immunoelectrophore sis, they detected radioactive AFP only in 
human and rat liver and rat yolk sac. Placenta and other organ systems 
were found not to be involved in the synthesis of alpha-fetoprotein. 
The function of AFP has not yet been elucidated. Smith^^ reported 




with severe congenital malformations, and he hypothesized that this 
protein may be necessary for normal organogenesis. He injected 
rabbit AFP antisera into the yolk sac of chicken eggs. Into a control 
group he injected non-immune normal rabbit sera. A similar experi¬ 
ment was performed injecting antisera intrape ritoneally into pregnant 
rats. 
Congenital abnormalities, failure of development or abortion 
occurred only in the experimental group. 50% of the chickens developed 
congenital abnormalities, and 40% of the eggs were dead and undeveloped. 
10% of the rats had meningomyeloceles, and 25% of the rat pregnancies 
terminated in abortion, stillbirth, or maternal mortality. As these 
results did not occur in the controls, it is unlikely that they are a result 
of a non-specific antigen-antibody reaction, but rather that alpha- 
fetoprotein has a physiological role in normal embryogenesis. 
Association with Neoplasms 
Prior to 1971 and the development of a radioimmunoassay for alpha- 
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fetoprotein, no one had been able to detect AFP levels in normal 
35 
healthy adults. However, Tatarinov, in 1965, demonstrated the pre¬ 
sence of a protein that was immunoelectropho retie ally identical to AFP 
in patients with primary liver cancer. 
This finding has been confirmed and expanded by many researchers, 




and, rarely, hepatitis. 7’ The frequency of detectable AFP levels 
in histologically verified hepatocellular cancer varies from between 
g 
38% and 81% in different parts of the world, with marked geographical 
and racial variation. ^ 
AFP in Pregnancy 
Whether AFP could be demonstrated in the serum of pregnant 
women had been a subject of controversy for some years. Foy and 
associates (1970), using immunodiffusion, found detectable AFP levels 
in 7 out of 20 pregnant women; all seven of them were more than 30 weeks 
pregnant. Alpert and Zuckerman (1970), ^ however, examined the sera 
from 142 pregnant women by electroimmunodiffusion and found no positive 
reactions. 
.27 
In 1971, Seppala and Ruoslahti developed a highly sensitive radio¬ 
immunoassay for AFP. They were able to detect levels in normal adults 
that ranged from 1. 5-16. 5 ng/ml. In examining the sera from 63 women 
at different stages of pregnancy and after delivery, they demonstrated 
30 
increasing AFP levels throughout pregnancy; during the first trimester, 
the range was from 18-119 ng/ml; during the second trimester the con¬ 
centrations were from 96 to 302 ng/ml; and during the third trimester, 
the AFP level ranged from 160 to 550 ng/ml. In three out of ten mothers, 
the concentration one day post-partum was greater than during labor. 
Maternal levels of AFP were found to fall rapidly during post-partum; 
the average half-life of maternal AFP was five days. 
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The question arose as to whether the pregnant women's elevated 
levels were a result of transplacental passage of alpha-fetoprotein 
produced by the fetus, or if metabolic changes in pregnancy caused the 
mother to produce this protein. Foy and associates^ had found that 
they could induce baboons to produce elevated levels of AFP by feeding 
them a pyridoxine deficient diet. Noting that pregnant women and women 
on oral contraceptives have a similar fall in serum pyridoxine levels, 
they compared AFP levels in pregnant women and women on oral contra¬ 
ceptives to see if such a vitamin deficiency could result in increased 
concentrations of AFP. By their immunodiffusion assay, none of the 
women on oral contraceptives had detectable levels of AFP, whereas 
35% of the pregnant women did. In addition, Foy and his co-workers 
examined the sera from the infants born to the women in the study; 
100% of the newborns had detectable levels, suggesting that the AFP 
levels seen in pregnant women were a result of transplacental passage. 
Amniotic and Fetal Levels of AFP 
Fetal levels of AFP have been well documented. Gitlin and Boesman 
(1966)^ found that fetal synthesis of AFP increases for the first twenty 
weeks of gestation, but that the concentration in fetal serum peaks at 
about 3 mg/ml at 13 weeks, and then begins to decrease as the fetus 
grows more rapidly than the production of AFP. Norgaard-Pederson 
22 
(1973) found a si gnificant correlation between gestational age and cord 
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serum AFP concentration; he calculated the 95% confidence limits 
for estimating gestational age by means of AFP concentration in cord 
blood to be + 16 days. 
O I 
Seppala and Ruoslahti (1972) L showed that gestational age can 
also be estimated by assaying amniotic fluid AFP. They used radio¬ 
immunoassay to determine the levels from 65 amniotic fluid samples. 
AFP concentration in amniotic fluid was found to decrease from the 
14th week of gestation until term. In the second trimester, the AFP 
levels ranged from 2,800-26,000 ng/ml, and during the third trimester, 
they ranged from 15-535 ng/ml. 
The correlation between gestational age and decreasing AFP con¬ 
centration in amniotic fluid was statistically highly significant (p< 0. 001). 
In addition, they found that all AFP levels in amniotic fluid prior to the 
37th week of pregnancy were 185 ng/ml or higher. 
The amniotic fluid sample from one infant with congenital nephrosis 
was markedly elevated to 4,900 ng/ml at 36 weeks gestation. Also, four 
samples of fetal urine were taken during the second trimester; AFP 
concentrations ranged from 5,900 to 48,000 ng/ml. These findings 




AFP in the Diagnosis of CNS Malformations 
Brock and Sutcliffe, in 1972, ^ undertook a retrospective study 
of alpha-fetoprotein in the amniotic fluids of 31 pregnancies leading 
to anencephaly, three leading to spina bifida, and three resulting in 
hydrocephaly. In the anencephalic cases, all AFP determinations 
made between 25 and 35 weeks ge station we re markedly elevated to 
between three and ten times normal levels; after 35 weeks gestation, 
five out of nine cases of anencephaly had AFP levels two to ten times 
normal. 
In one case of spina bifida in which the fluid was obtained at 13 
weeks, AFP concentration was four times the upper limit of normal. 
Amniotic fluid samples from pregnancies resulting in spina bifida or 
hydrocephaly that were obtained after 30 weeks gestation did not show 
any increase in AFP. 
Following the experiences of Brock and Sutcliffe, other investigators 
initiated prospective studies on women who were at risk for having an 
anencephalic child due to a previous pregnancy resulting in anencephaly. 
Several investigators reported terminating pregnancies at 18 to 20 weeks 
gestation when an AFP level of five to twenty times normal was detected. 
In all cases the aborted fetus had anencephaly ’ or a large myelocele. 
Harris and co-workers^ compared amniotic fluid and maternal 
serum AFP levels in the early diagnosis of neural tube defects. They 
found raised amniotic levels in anencephaly and "open" spina bifida 
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and normal levels in association with closed lesions, including 
2 8 
encephalocele and hydrocephalus. Seller's group also examined 
the serum AFP concentration in seven anencephalic fetuses and found 
them to be normal for their gestational age. These findings suggest 
transudation of fetal blood components as the mechanism of the elevated 
amniotic AFP levels with neural tube defects. 
Radioimmunoassay was employed by Harris' group^ in evaluating 
maternal serum. Their samples from pregnancies involved in CNS 
malformations were from the second and third trimesters and yielded 
results within the normal range in eight out of nine cases, including 
open spina bifida and anencephaly. The isolated elevated maternal 
level occurred in the case of a spontaneous abortion of an anencephalic. 
28 
Similarly, Seller and co-workers found maternal serum AFP 
concentrations unreliable in indicating neural tube defects. They con¬ 
cluded that closed neural tube lesions will usually be missed by assaying 
for AFP, and that maternal concentrations of AFP cannot be relied 
upon to indicate CNS malformations in early pregnancy. 
AFP in Fetal Stress 
Alpha-fetoprotein represents a fetal marker in maternal serum 
as well as in amniotic fluid, and currently the AFP levels in several 
types of high-risk pregnancies are being documented. Vivian and Ward^ 
recently examined maternal AFP levels in Rh-immunized pregnancies. 
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They found all fifteen of their samples to fall within the normal range. 
Three samples represented pregnancies which resulted in stillbirths, 
and in two of those cases the maternal serum was drawn within 
twenty-four hours before death. They therefore concluded that evalu¬ 
ating maternal AFP concentrations is not helpful in assessing fetal 
distress in Rh disease. 
32 
Seppala and Ruoslahti studied the AFP levels in maternal serum 
and amniotic fluid in 48 pregnancies complicated by maternal immuniza¬ 
tion against Rh and ABO systems. In examining the maternal serum, 
they found the AFP concentrations in the immunized women to be 
significantly higher than the normal controls; however, in most cases 
(41 out of 48) the AFP levels were within normal limits. Three samples 
that were above normal limits represented severe Rh-immunization 
leading to intrauterine fetal death. 
The AFP concentrations in the amniotic fluid samples from Rh 
disease were found to be uniformly distributed around the normal 
median. Samples from three cases of severe erythroblastosis, and 
one sample obtained four days prior to fetal death were all above the 
normal median. In two of the cases of severe erythroblastosis, the 
concentrations of AFP were found to increase, instead of decrease, 
with advancing gestation. 
Seppala and Ruoslahti concluded that amniotic and maternal serum 
-AFP concentrations may be elevated in severe Rh-immunization but 
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usually remain within the wide range of normal limits. They also 
inferred that amniotic AFP levels may paradoxically rise with gesta¬ 
tional age in the face of severe erythroblastosis fetalis. 
They speculated that the raised maternal AFP levels in fetal 
distress may be either primary or secondary to the fetal disease. 
The elevated AFP may be the result of increased fetal-maternal 
transfusion, which would boost maternal immunization and lead to 
more severe disease. 
Or possibly, the increased concentration could be secondary to 
disease; it could reflect higher fetal production of the protein, perhaps 
as a result of delayed fetal liver maturation due to prolonged stress. 
17 
Higa and co-workers compared normal amniotic levels of twenty 
proteins, including AFP, with samples from pregnancies that resulted 
in Down's Syndrome, anencephaly, and fetal death. They found that 
the total protein concentration in amniotic fluid was not useful in ante¬ 
natal diagnosis of those entities, but that IgM, IgA, IgG and AFP were 
elevated in cases of anencephaly and fetal death. These findings agreed 
with those of Seller ^ and Harris;'"^ in examining serial samples from 
cases of anencephaly, they found markedly elevated concentrations of 
AFP that decreased with gestational age but always remained three to 
ten times normal. 
Higa's group also looked at maternal serum levels of AFP in a 
case of fetal death and found it to increase with fetal demise: 
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Gestational Age Maternal AFP 








Seppala and Ruoslahti (1973) reported the amniotic AFP concen¬ 
trations in ten abnormal pregnancies. They noted marked elevations 
in two out of four cases of fetal death, including one in which the amniotic 
AFP level rose from 400 ng/ml one week prior to death to 48, 000 at 
death. 
They described three pregnancies in diabetic women in v/hich the 
amniotic fluid AFP concentrations showed a small but surprising increase 
late in gestation. They also noted a slightly elevated concentration in 
the earlier samples from the diabetics. Seppala and Ruoslahti stated 
that the increases in AFP were associated with fetal distress, but they 
failed to elaborate. 
2 3 
Norgaard-Pede rsen and Klebe (1974) determined the AFP concen¬ 
tration in cord blood from 45 newborns of diabetic mothers. They found 
a significantly (p<0. 05) higher concentration of AFP in infants of insulin- 
treated mothers than in ge stationally matched normals. The AFP con¬ 
centration in the five infants of non-insulin dependent diabetics fell 
within normal limits. 
In summary, AFP has been found to be a major serum protein of 
the fetus. In normals it reaches a maximum serum concentration of 
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3 mg/ml at 13 weeks gestation. From this level it decreases at a 
predictable rate until at birth it is approximately 1% of the peak level, 
and by one year of age, the concentration is less than 0. 001% of the 
peak level. 
AFP concentration in the amniotic fluid parallels fetal serum levels 
of the protein except when malformations result in excessive transuda¬ 
tion of the protein. Maternal serum concentrations of AFP, however, 
increase throughout pregnancy, and rapidly fall during the first post¬ 
partum week. Elevated adult levels of AFP have also been demonstrated 
in association with hepatomas and malignant teratomas. 
Extremely elevated concentrations of AFP have been documented in 
the maternal serum and amniotic fluid in cases of open neural tube 
defects. Some investigators have reported increased levels with fetal 
demise and fetal stress in Rh-immunization and diabetes. 
The association of massively elevated amniotic AFP levels with 
neural tube defects is presently used at many centers as evidence for 
elective termination of affected pregnancies. A radial immunodiffusion 
assay is employed at this hospital to determine if an at-risk pregnancy 
is affected with a CNS malformation. It is the purpose of this investi¬ 
gation to examine the use of the radial immunodiffusion assay of AFP 
in exposing other forms of fetal distress. 

MATERIALS AND METHODS 
Study Group 
82 amniotic fluid samples from 77 pregnancies were studied: 42 
from the second trimester and 40 from the third. Amniotic fluid was 
obtained at the time of cesarean section or by transabdominal amnio¬ 
centesis and was kept frozen until assayed. 
Control samples for the second trimester were obtained from 
patients undergoing elective abortion for social reasons or a genetic 
tap that later resulted in a normal pregnancy. Controls for the third 
trimester of pregnancy came from patients undergoing elective repeat 
cesarean section or amniocentesis for determination of fetal maturity. 
Samples for pregnancies at risk for fetal stress included those 
with the maternal complications of Rh-immunization, diabetes mellitus, 
and pre-eclampsia, as well as congenital malformations. Also included 
in the study were sera collected from eight women at the time of amnio¬ 
centesis. 
Radial - Immunodiffusion 
Alpha-fetoprotein was measured by radial immunodiffusion as 
originally described by Mancini. A monospecific rabbit antiserum 




supplied by Dr. Alexander Baumgarten. The purity of the AFP standard 
was checked by spectrophotometry, and the concentration of 6. 6 micro- 
grams/mililiter was confirmed by an outside laboratory. 
Alpha-fetoprotein agarose was prepared using 1 gm. agarose, 
0. 1 gm. sodium azide, and 100 ml. normal saline. 16 ml. of AFP- 
agarose was mixed with 100 ul AFP-antisera at 50°C. The mixture 
was allowed to gel on a 8. 2 x 10. 1 cm. glass plate at 4°C, and then 42 
3 mm. wells were punched in the gel. The wells were filled with 20 ul 
of fluid. Standards were used to fill the wells around the perimeter of 
the slide; in this way they not only served as known concentrations of 
AFP, but they also determined if the film of agar was uniform across 
the plate. The standards used were 3. 14 ug/ml, 2. 00 ug/ml, 1. 04 ug/ml, 
and 0. 43 ug/ml. 
All amniotic fluid samples were initially diluted 1:5 with normal 
saline. All cloudy, blood-tinged, or meconium-stained fluids were 
centrifuged at 1700 rpm for 30 minutes to remove cellular debris before 
the dilutions were made. Every sample was assayed twice on a plate. 
The plates were allowed to incubate in a moist environment at 
room temperature for 48 hours. In the manner first described by 
Alpert and co-workers in 1970, the plates were then washed in saline 
for 24 hours and then placed in a 1% tannic acid solution for 15 minutes 
in order to highlight the precipitin rings. 
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Radial-immunodiffusion works on the principle that the antigen 
placed in the well will combine with an equivalent amount of antibody 
that is contained in the agar. When all of the antigen has been con¬ 
sumed, a ring of antigen-antibody complex will remain indefinitely, 
provided that the antiserum is incapable of redissolving the precipitin. 
Mancini proved a linear relationship between the concentration 
of antigen originally placed in the well and the area of the precipitin. 
Using that principle, the square of the diameters of the standards' 
precipitin rings were plotted against their known concentrations. The 
resulting graph was used to calculate the concentration of AFP in the 
unknowns. 
Samples whose precipitin rings were larger than all of the stan¬ 
dards were repeated at dilutions of 1:10 and 1:15. Fluids that failed to 
produce a ring, or whose ring was smaller than the smallest standard, 
were repeated undiluted. 
In order to increase the sensitivity of the technique, agar plates 
were prepared using only 75 ul of antisera/16 ml of agar and 50 ul 
antisera/16 ml agar. In addition, new standards were prepared with 
330 ng/ml, 210 ng/ml, 165 ng/ml, 132 ng/ml, and 110 ng/ml. Every 
sample that failed to produce a measurable ring in the initial assay was 
repeated undiluted with smaller concentration of antisera. 
f 
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Evaluation of the Method 
It was found that 16 ml of AFP agarose needed at least 50 ug 
antisera to yield readable precipitin rings. Using that concentration 
of antisera, it was possible to detect standards diluted as much as 
1:400, or 165 ng/ml. At 1:500 dilution, or 133 ng/ml, no precipitin 
rings were seen. At dilutions greater than 1:150 (440 ng/ml) the slope 
of the dose - re sponse curve began to flatten as the accuracy of the 
assay decreased and the limit of sensitivity was approached. By 
using the least possible concentration of antisera in the agar, the 
change in the slope was minimized. Figure 1 demonstrates the dose- 
response curve and the sensitivity and accuracy limits of the assay. 
The with-in assay variability of the diameters of identical stan¬ 
dards plated five times throughout a plate was 1. 2%. All samples 
were plated in duplicate on each slide. 
The between-assay variability was more complex. Results that 
could be read at 1:5 dilution were replated at the same dilution and 
gave a between-assay co-efficient of variation of 10%. Higher concen¬ 
trations that were diluted 1:10 and 1:15 gave a variability of 9%. Small 
concentrations between 0. 5 and 0. 8 ug/ml had a co-efficient of varia¬ 
tion of 13%. Samples with a mean concentration between 0. 2 and 0. 5 
ug/ml, however, showed a standard deviation of + 0.1 and a co-efficient 
of variation of 33%. 

RESULTS 
The AFP concentrations were assayed and recorded without 
prior knowledge of the identity of the sample. Gestational age was 
determined by ultrasound evaluation of biparietal diameter, and, 
where possible, the pediatrician's examination of the newborn. A 
graphic representation of the results is recorded in Figure 2. 
37 control samples from the second trimester had a mean value 
of 7 ug/ml with a range of 2. 4 to 17. 5 ug/ml. 26 samples from ges¬ 
tational age 15-18 weeks had a mean concentration of 8. 6 ug/ml, with 
a range of 2. 6-17. 5 ug/ml; the 11 samples from 19-22 weeks gestation 
ranged from 2. 4-9. 1 ug/ml with a mean value of 4. 2 ug/ml. This 
range of normal AFP concentration is in agreement with the findings of 
other investigators using different assay techniques. ^ 
Four amniotic fluid specimens from the second trimester were 
from pregnancies in which the fetus could be considered at risk for 
distress; all samples were found to have concentrations within the range 
of normal. Another specimen was from a fetal death complicated by 
Rh disease and trisomy 18. The AFP concentration was assayed to be 
16. 2 ug/ml which is well above the mean for that gestational age. 











methadone maintenance 2. 7 
diabete s 4.6 
twins 5. 2 
meconium staining 6. 5 
Rh disease, 18^, fetal death 16. 2 
Samples from the third trimester included specimens from two 
anencephalics in which the AFP concentration was over 20 ug/ml. The 
other 38 specimens were obtained after the 32nd week of gestation and 
all had AFP concentrations less than 0. 8 ug/ml. The samples came 
from normal pregnancies and pregnancies complicated by diabetes 
(both Class A and B), Rh-disease, and pre-eclampsia. 
With the exception of the anencephalics, all detectable levels in the 
third trimester samples were found to be between 165 and 800 ng/ml. The 
co-efficient of variation at this concentration was 33%; it was decided, 
therefore, to group together for statistical evaluation, all samples 
that yielded a visable precipitin ring yet had a concentration less than 
800 ng/ml. All samples that, undiluted, failed to produce a definite 
precipitin ring on any plate were defined as having undetectable levels 
of alpha-fetoprotein, or an AFP concentration less than 165 ng/ml. The 
results are shown graphically in Figure 3. 
The amniotic fluid samples taken from nine normal pregnancies 
between the 36th and 40th week of gestation all had concentrations of 




from an otherwise uncomplicated pregnancy had an undetectable AFP 
level. 
Finding the concentrations of AFP at term in normal pregnancies 
to be under 165 ng/ml is in agreement with the work of Seppala and 
28 
Ruoslahti. Using radioimmunoassay, they found the AFP concentra¬ 
tion at 37-38 weeks averaged 164 ng/ml; at 39-40 weeks the mean con¬ 
centration was 115 ng/ml; and at 41-42 weeks, the level had decreased 
to 87 ng/ml. 
18 samples from pregnancies stressed by Rh-disease, diabetes, 
and toxemia were obtained during the last four weeks of pregnancy. 
Only four of those specimens had undetectable levels of AFP. There 
O 
was a highly significant correlation ( ^ =14. 6, p<0. 0005) between the 
stress factors of diabetes, Rh-disease, and toxemia, and concentrations 
at term of AFP greater than 165 ng/ml. 
Twelve of the fifteen samples from diabetics at term had detectable 
levels of AFP. Diabetes was shown to have a high correlation with 
increased levels of AFP (^-[4, 4^ p<0. 0005). 
Six samples from Rh- immunized pregnancies were assayed, and 
all were found to have detectable levels of AFP. Five of the six, though, 
were obtained before the 36th week of gestation, and no normal samples 
were available for comparison. Two specimens from 34 and 35 weeks 
are of special note, however. They represented an infant that suffered 
from erythroblastosis fetalis, with 2+ jaundice at birth, 1-2+ edema, 

19 
Apgar scores of 3/6, and an initial hematocrit of 36. The infant was 
definitely stressed by its disease; however, AFP levels obtained one 
week prior to birth and at delivery were both 300 ng/ml. That AFP 
concentration is well within the range of normal seen by Seppala and 
28 Ruoslahti in the 34-35 week gestational period. 
This study, therefore, failed to show any relationship between 
Rh-immunization and elevated amniotic fluid AFP concentration. The 
32 
investigation of Seppala and Ruoslahti similarly failed to demonstrate 
a correlation between abnormal amniotic fluid AFP levels and Rh- 
immunization. 
Five samples were obtained from women who had been treated for 
toxemia of pregnancy during the last trimester. Four out of five had 
concentrations of 500 ng/ml or greater, but two of the samples were 
obtained during the 34th and 35th weeks of gestation with no normal 
controls. Unfortunately, three samples obtained at term did not 
represent a sufficient volume to show a statistically significant correla¬ 
tion between elevated AFP levels and toxemia Q 2 = 3. 4, p<0. 07). 
Of particular interest is a sample from a 40-week gestation in a 
diabetic pre-eclamptic mother. The AFP concentration was assayed 
to be 800 ng/ml, the highest AFP level of any sample obtained at term# 
The infant involved was noted to suffer from transient hypoglycemia. 
The AFP level of 600 ng/ml at 36 weeks reflected a premature infant 
who was treated for prolonged hypoglycemia. 
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Three diabetics and one woman with Rh disease had more than 
one amniocentesis as term approached; they all showed AFP concen¬ 
trations that decreased or remained constant with increasing gestation. 
The findings are summarized below. 
Compli cation Gestational Age AFP ng/ml. 
Diabetic Class A 37 weeks 400 
38 300 
39 300 
Diabetic Class A 38 weeks 300 
39 Undete ctable 
Diabetic Class B 37 weeks 400 
38 300 
Rh disease 34 weeks 300 
35 300 
Eight serum samples were taken from women undergoing amnio¬ 
centesis at term. All of the women had either Rh-disease or diabetes, 
and they all showed a serum level of 350 ng/ml (S. D„ + 100 ng/ml) 
which is within the range of normal for this gestational period according 
31 
to the work of Seppala and Ruoslahti. 

COMMENT 
Unfortunately, the radial-immunodiffusion technique is not 
sensitive enough to make a more detailed analysis of the AFP levels 
late in pregnancy. The low accuracy at concentrations less than 1. 0 
ug/ml made it impossible to compare groups with mildly elevated 
AFP levels. However, the assay does show a significant increase in 
amniotic fluid AFP in the face of diabetes and suggests an elevation in 
response to prolonged toxemia of pregnancy. 
Alpha-fetoprotein is a major serum protein of the fetus and serves 
as a parameter of several aspects of fetal life. Elevated amniotic AFP 
concentration can reflect either increased fetal production of AFP or 
increased transudation of the protein. The high levels seen in anencephaly 
are an example of the latter. 
Slightly but significantly elevated levels of AFP in association with 
maternal diabetes and pre-eclampsia cannot easily be explained by 
increased transudation. Norgaard-Pede rsen and Klebe demonstrated 
increased AFP levels in the serum of infants of diabetic mothers. 
Seppala and Ruoslahti theorized that elevated amniotic levels might 
be the result of increased fetal production of the protein. 
One can postulate that elevated AFP production results from delayed 
3 o 




levels in patients with ataxia-telangiectasia. One of the theories to 
explain the disorder is that there is a defect in the interaction between 
the entoderm and mesoderm that is required for normal tissue dif¬ 
ferentiation, resulting in a failure of maturation of gut-associated 
organs. They found abnormally high serum levels of AFP in all patients 
with ataxia telangiectasia, suggesting an association between increased 
AFP and retarded differentiation. 
Gitlin and Boesman^ had demonstrated in the human fetus a direct 
relationship between an increase in the production of albumin and a 
turning off of the synthesis of AFP. Coid' demonstrated in mice a 
significant relationship between mild maternal infection, intrauterine 
growth retardation, and a low albumin/AFP ratio, indicating again 
that elevated AFP may be a reflection of neonatal immaturity in response 
to stress. 
Two major theories have been suggested to describe the dynamics 
of AFP synthesis. These hypotheses have been proposed by cancer 
researchers to explain the production of AFP in hepatoma. Abelev1 
attributes the synthesis of AFP to the "hepatoblast, " a specialized liver 
cell that predominates in fetal livers, and with maturity of the fetus is 
overrun by the hepatocyte. 
3 6 
Uriel hypothesizes that there is only one type of liver cell. 
According to this theory, the genetic code for AFP production is turned 
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on during fetal life and is repressed with maturity. Under either view, 
the increased production of AFP reflects the presence of immature 
liver cells. 
39 
Zetterstrom and his colleagues in 1958 described an increased 
frequency of non-hemolytic hyperbilirubinemia in 29 newborn infants 
of diabetic mothers. They hypothesized that the hyperbilirubinemia 
could reflect "immaturity-for-dates" in the infants. 
Heringova's group, ^ however, compared the bilirubin clearance 
in normal newborns with the clearance rate in prematures and diabetics. 
They found that all groups had equal difficulty handling an increased 
bilirubin load on the first day of life; but on day five, both normals and 
diabetics rapidly secreted 100% of a test dose, whereas premature infants 
responded as sluggishly as they had on (jay one. They concluded that the 
hyperbilirubinemia seen in infants of diabetic mothers may be of different 
origin than that seen in premature infants. 
18 
Jersova and co-workers were able to show a significant decrease 
in bilirubin excretion and choleresis in infant rats injected with serum 
from diabetic mothers as compared to rats injected with serum from 
normal pregnant women. They hypothesized that diabetic serum contains 
a factor that can inhibit choleresis and bilirubin excretion. 
The mechanism responsible for the increased incidence of non¬ 
hemolytic hyperbilirubinemia in infants of diabetic mothers remains 
unclear. Perhaps the elevated AFP production in these infants is a 
parallel phenomenon and reflects liver immaturity. 

24 
It has been suggested that many of the clinical manifestations seen 
in infants of diabetic mothers can be explained by the following patho- 
25 r 
genetic sequence: maternal hyperglycemia, causing fetal hyperglycemia 
and hypertrophy of the fetal pancreatic islets, leading to fetal hyper- 
insulinism. This combination of hyperinsulinism and hyperglycemia 
results in increased hepatic glucose uptake and glycogen synthesis, 
accelerated lipogenesis, and augmented protein synthesis. This process, 
resulting in increased protein synthesis, may be the sole causative agent 
in the elevated levels of alpha - fetoprotein seen in these infants. However, 
this explanation fails to describe adequately why a fetal protein is elevated 
at term: perhaps the increased protein synthesis delays liver maturation, 
thereby elevating AFP production. 
It has been demonstrated that alpha-fetoprotein is very useful diag¬ 
nostically in fetal neural tube defects, and these data presented here sug¬ 
gest a possible correlation between fetal jeopardy in pregnancies compli¬ 
cated by diabetes and toxemia and increased concentrations of AFP. For 
late gestational analysis, the more complicated yet more sensitive radio¬ 
immunoassay would be helpful. A large study of RIA determined AFP 
levels at term in high-risk pregnancies has not been undertaken, and 
might help answer many questions about fetal development. 

SUMMARY 
Alpha-fetoprotein is known to be a useful diagnostic tool for early 
detection of fetal neural tube defects. Investigations have indicated 
that AFP can also be used to estimate gestational age and that abnormally 
elevated levels of AFP are often associated with fetal demise or fetal 
distress. 
A radial immunodiffusion assay was used in this investigation to 
determine the AFP concentration in 80 amniotic fluid samples from the 
second and third trimesters of pregnancy. Anencephalic fetuses had 
amniotic fluid concentrations of AFP that were ten times normal. The 
levels of AFP in the second trimester were found to have a wide range 
of normal: 2-17. 5 ug/ml. A sample from a fetal death at 20 weeks gesta¬ 
tion had a concentration at the upper limit of normal. 
The AFP level at term when the mother was diabetic was found to 
be significantly higher (p<0. 0005) than normal controls. Concentrations 
when the pregnancy was complicated by toxemia were elevated, but the 
difference was not statistically significant (p<0.07). In cases of Rh 
immunization, the AFP levels were not found to be elevated. 
The possible etiologies of increased AFP concentrations were dis¬ 
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Figure 3: Tore response curve of the immunodiffusion 
assay for AFP with standard deviations 
graphed at different concentrations. 
The slope of the curve is noted to flatten at concentretions 
less than 1 ug/ral. This dose-response curve demonstrates 
that ?t the low®r limit of the assay, very small changes 
in the diameter of the precipitin ring result in significant 
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Figure 2: AFP concentrations at different gestational 
Fean concentrations of AFP during the second trimester 
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Figure 3s AFP concentrations in the third trimester 
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